Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The embryonic origins of site-specific arthritis.

Nature immunology·2026

Same author

Targeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure?

Rheumatology (Oxford, England)·2026

Same author

Tissue resident memory T cells populate the human uveal tract.

Scientific reports·2026

Same author

CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions.

Molecular medicine (Cambridge, Mass.)·2026

Same author

Cellular and molecular landscapes of human tendons across the lifespan revealed by spatial and single-cell transcriptomics.

Cell reports·2026

Same author

Tissue Damage in Rheumatoid Arthritis Is Genetically Linked to Low Peptidylglycine Alpha-Amidating Monooxygenase Activity in Synovial Fibroblasts.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis

Published on: February 13, 2026

Immune interactions in hepatic fibrosis.

Andrew P Holt¹, Mike Salmon, Christopher D Buckley

¹Liver Research Group, MRC Centre for Immune Regulation, University of Birmingham, Birmingham, UK.

Clinics in Liver Disease

|November 6, 2008

Summary

Liver cirrhosis develops from repeated liver injury and inflammation. Immune system interactions with liver cells regulate fibrosis and scarring, impacting tissue repair and homeostasis.

More Related Videos

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Related Experiment Videos

Last Updated: Jun 28, 2026

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis

Published on: February 13, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Area of Science:

Hepatology
Immunology
Cell Biology

Background:

Liver cirrhosis results from chronic inflammation and tissue repair cycles.
Persistent inflammation and matrix remodeling lead to liver fibrosis and scarring.
Wound healing mechanisms involve complex interactions within the liver microenvironment.

Purpose of the Study:

To elucidate the role of the immune system in liver fibrosis and cirrhosis development.
To understand the cellular interactions governing scar formation in chronic liver injury.

Main Methods:

This study reviews the interplay between immune cells, stromal cells, and extracellular matrix components.
Analysis of cytokine, growth factor, and matricellular protein roles in liver repair.

Main Results:

The immune system is central to regulating fibrosis, tissue repair, and homeostasis in the liver.
Chronic inflammation and fibrosis are closely linked processes.
Cellular interactions between immune cells, fibroblasts, and macrophages determine liver injury outcomes.

Conclusions:

Understanding immune system regulation of fibrosis is crucial for managing liver cirrhosis.
Targeting cellular interactions may offer therapeutic strategies for liver scarring.